Comparison Study of Dendritic Cell Vaccine with and without Cyclophosphamide to Treat Stage IV Melanoma Patients

This trial is evaluating whether the combination of chemotherapy (cyclophosphamide) and CD34-DC vaccines results in the improved rate of clinical responses for stage IV melanoma patients.

Study Type: Interventional

Age/Sex Requirement: 21-75 years (None)

Sponsor: Baylor Research Institute

ClinicalTrials.gov Identifier: NCT00722098

Purpose: To determine whether the combination of chemotherapy (cyclophosphamide) and CD34-DC vaccines results in the improved rate of clinical responses for stage IV melanoma patients.

Click here to learn more about the clinical trial.